Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
CG Oncology, Inc. - Common stock
(NQ:
CGON
)
37.02
+1.09 (+3.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about CG Oncology, Inc. - Common stock
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
June 18, 2024
- First Patient Dosed in Expanded Access Program and Enrollment Ongoing -
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
June 06, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
May 24, 2024
54% complete response (CR) rate at 24-month landmark and meets primary endpoint of the phase 2 study
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
May 09, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 03, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
April 26, 2024
Company to host virtual investor event on Friday, May 3, 2024, at 4:30pm EDT following presentation of results from the Phase 3 BOND-003 trial at the 2024 AUA Annual Meeting
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
April 24, 2024
- Final results of CORE-001 Phase 2 trial of cretostimogene in combination with pembrolizumab for the treatment of BCG-unresponsive NMIBC -
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
March 28, 2024
- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session -
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
February 27, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
3 attractive stocks that insiders are buying
February 12, 2024
The insiders are buying these attractive stocks. With a bank, a tech, a penny stock, a dividend payer, and a pharmaceutical winner, there is something for all.
Via
MarketBeat
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 30, 2024
From
CG Oncology, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.